N/A
N=180
Variability in Perimetry Study
Glaucoma
Bottom Line
View on ClinicalTrials.gov: NCT01051739 ↗Enrolled (actual)
180
Serious AEs
0.0%
Results posted
Feb 2017
Primary outcome: Primary: Number of Subjects Progressing in Each Group Using Pointwise Linear Regression — 0; 0 participants — p=.21
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Comparison of four visual field testing strategies (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- VA Office of Research and Development
- Primary completion
- Sep 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Subjects Progressing in Each Group Using Pointwise Linear Regression |
0; 0 | .21 |
Summary
Improved Assessment of Visual Field Change is a trial aimed at investigating mechanisms of visual field testing variability. The investigators have found using larger stimulus size substantially lowers short-term variability. In this study, the investigators will determine if larger stimuli detect visual field change at an earlier time. The investigators are also developing a statistical model that accounts for correlations of neighboring test locations.
Eligibility Criteria
Inclusion Criteria
- Mean deviation of -20 or better with 5-8 points (optimally 10 points) with a value of p= 0.05 or better on the total deviation plot
- Mild cataract with VA of 20/30 or better pinholed
- Refractive error of = to or less than 6 diopters with = or less than 3.50 diopters of cylinder
- Pupil diameter of 3 mm minimum
- Controlled hypertension, diabetes, migraine
- Pseudophakic/refractive surgery if no vision problems
- Trabeculectomy okay
Exclusion Criteria
- History of other ocular or neurologic disease or surgery
- History of stroke
- Systemic disease [lupus, graves, cancer (within the last 5 yrs), AIDS, other]
- History of amblyopia
- Unreliable patient
- Frequently misses appointments
- Tests poorly
- Ocular hypertension
- Retinal problems
- Diabetic retinopathy
- Neurological disease (IIH, ON, AION)
- Cancer not in remission for the last 5 years
- Vein or artery occlusions
- Macular degeneration
- Trauma with vision loss
- Ocular inflammation (pars planitis, iritis, temporal aeuritis)
Data sourced from ClinicalTrials.gov (NCT01051739). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.